Compass Therapeutics (NASDAQ:CMPX) Downgraded to "Hold" Rating by Lifesci Capital

Key Points

• Lifesci Capital downgraded Compass Therapeutics from “Strong Buy” to “Hold,” although the broader analyst consensus remains “Moderate Buy” with an average price target of $10.21.
• Compass shares opened at $1.17, near their one-year low of $1.13, while the company reported a quarterly loss of $0.13 per share—$0.02 worse than analysts expected.
• Institutional investors own 68.43% of the stock, with several hedge funds recently establishing or expanding positions; however, additional FDA-requested clinical testing could delay development of tovecimig and increase costs.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) was downgraded by investment analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating in a report issued on Tuesday, Zacks reports.

Other equities research analysts have also recently issued reports about the stock. Guggenheim cut their price objective on shares of Compass Therapeutics to $4.00 and set a "buy" rating for the company in a research report on Wednesday. LADENBURG THALM/SH SH began coverage on Compass Therapeutics in a report on Wednesday, July 1st. They issued a "buy" rating and a $5.00 price objective on the stock. Stifel Nicolaus set a $6.00 price objective on Compass Therapeutics in a research report on Monday, June 1st. Piper Sandler lifted their target price on Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Finally, Citizens Jmp lowered their price target on Compass Therapeutics to $4.00 and set a "market outperform" rating for the company in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.21.

Compass Therapeutics Stock Performance

NASDAQ:CMPX opened at $1.17 on Tuesday. Compass Therapeutics has a one year low of $1.13 and a one year high of $6.88. The stock has a market cap of $210.71 million, a PE ratio of -2.92 and a beta of 0.95. The stock has a 50 day moving average price of $2.12 and a 200 day moving average price of $2.93.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). As a group, analysts predict that Compass Therapeutics will post -0.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds have recently bought and sold shares of the company. Palo Alto Investors LP acquired a new stake in shares of Compass Therapeutics during the second quarter worth about $12,771,670. BlackRock Inc. purchased a new stake in shares of Compass Therapeutics in the 2nd quarter valued at approximately $24,707,000. Squarepoint Ops LLC raised its holdings in shares of Compass Therapeutics by 1,906.9% in the 2nd quarter. Squarepoint Ops LLC now owns 1,007,507 shares of the company's stock valued at $2,206,000 after purchasing an additional 957,305 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Compass Therapeutics by 224.9% in the 1st quarter. Bank of America Corp DE now owns 865,613 shares of the company's stock valued at $4,579,000 after purchasing an additional 599,179 shares in the last quarter. Finally, Royce & Associates LP purchased a new stake in shares of Compass Therapeutics during the 4th quarter worth $1,536,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Compass Therapeutics News Summary

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Citizens JMP maintained a Market Outperform rating but lowered its price target to $4.00. The target implies substantial potential upside if Compass successfully addresses regulatory concerns and advances tovecimig toward approval.
• Positive Sentiment: Compass said it intends to continue pursuing the program despite the FDA feedback, signaling that management believes tovecimig remains commercially viable and that the additional regulatory requirements can be addressed. Compass vows to press on with FDA application despite new trial request
• Neutral Sentiment: Analysts and commentary described tovecimig as having a promising opportunity in biliary tract cancer, but warned that the development and regulatory window is becoming narrower, increasing execution risk. Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity
• Negative Sentiment: The FDA recommended that Compass conduct a trial demonstrating a survival benefit in previously treated, advanced biliary tract cancer before submitting a Biologics License Application. This could materially delay a potential filing, raise development costs and require additional financing. Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
• Negative Sentiment: Wedbush downgraded CMPX from Outperform to Neutral and cut its price target to $1 from $5, citing the FDA’s additional-trial request and estimating further downside. LifeSci Capital also downgraded the stock to Hold. Wedbush Downgrades Compass Therapeutics

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company's research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.